NKTX

Nkarta, Inc. (NKTX) | Rumor.io

Nkarta

NKTX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,738

Bullish sentiment (50-day avg)88%

Price to earnings ratio-1.9

Market capitalization191.2M

Earnings per share-1.59

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-104.1M

Social

What share of all stock conversation is about NKTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Apr 17

$NKTX is moving up approximately 30% in 3 weeks, potentially offering a 30% return on investment.
The company's engineered NK approach may show even stronger efficacy in treating RA, allowing it to capture some of the excitement around $ARTV.
The CEO's hint that the company is moving into RA with their engineered NK approach has been well-received, with some analysts expecting the stock to break over $4.

Generated by AI

Sentiment

Of the messages about NKTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	93.42% +9.21	96.08% +65.04	86.01% +9.87
Bearish	—	6.58% -9.21	3.92% -65.04	13.99% -9.87

Bullish· Mar 27

$NKTX is breaking out over previous intraday highs, and holding above this resistance could lead to further gains.
The company's cost-cutting measures and extended cash runway into 2029 have contributed to its recent 50%+ price increase, with analysts holding $14-$18 targets.
With 4 trials underway for NKX019 in the autoimmune space, momentum is building, and volume remains strong, suggesting the stock could continue to run.

Bearish· Jan 10

$NKTX is likely to decline at the market open after a one-day surge.
The stock is overvalued and may be due for a correction.
$NKTX is heavily shorted and may experience a significant price drop if it fails to reclaim recent gains.

Generated by AI

Topics

Of the messages about NKTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	60.64%
Technical Analysis	—	0%	0%	35.34%
Analysts	—	0%	0%	4.02%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Mar 27

Nkarta, Inc. ($NKTX) laid off 1/3 of its workforce, including senior leadership, resulting in a stock price increase.
The company reported Q4 and full-year 2024 results, highlighting ongoing trials of NKX019 in rheumatic and neurological diseases with initial data expected in H2 2025.
Nkarta implemented a 34% workforce reduction to extend its cash runway by over a year, ensuring ample funds for ongoing trials and research.

Technical Analysis· Mar 27

$NKTX needs to break over downtrend for entries and close over resistance for a bounce.
$NKTX has broken out over previous intraday highs and needs to hold above that resistance for continued momentum.
$NKTX has strong upwards move and is trending upwards, breaking over Volume Weighted Average Price, with a possible run to $5.

Generated by AI

Community

Of the messages about NKTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.92%	69.13%	59.42%
Newcomers	—	33.08%	30.87%	40.58%

Regulars· Mar 25

$NKTX's secondary offering at $10/share, priced at $240M, has raised concerns about the company's financial struggles and potential impact on future growth.
The promising results for five patients with non-Hodgkin lymphoma, which led to a reversal of the company's Friday dive, may not necessarily translate to similar results for lupus treatment.
Nkarta's recent underwritten offering has sparked debate over its future growth potential, with one analyst noting that the company's recent trend of 33 price movements in the past 24 hours may be a cause for concern.

Newcomers· Jan 9

$NKTX is showing signs of consolidation, with price above its 10-day EMA, and a potential inside day forming.
The stock has experienced a significant 77% move, with a 99% Relative Strength (RS) over 1, 3, and 6 months, indicating strong momentum.
The company is pursuing a treatment for lupus, and the stock has seen a nearly 10x increase since its October low, with the next potential target being $CABA.

Generated by AI

Nkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is developing an allogenei

2d agoYahoo Finance

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Two abstracts selected for oral presentations, highlighting investigational CAR-NK cell therapy’s clinical activity in idiopathic inflammatory myopathy and overall safety profile Third abstract selected for poster presentation highlighting NKX019’s clinical activity in systemic sclerosis SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineered natural killer (NK) cell therapies to treat autoimmune di

22d agoYahoo Finance

Also Discussed

Investors talking about NKTX also mention

#	Name	Attention
1	IGMS - IGM Biosciences, Inc.	——
2	Veru Inc.VERU	0%0
3	Immatics N.V.IMTX	0%0
4	Nutex Health Inc.NUTX	0%new
5	TScan Therapeutics, Inc.TCRX	0%0
6	Caribou Biosciences, Inc.CRBU	0%0
7	FRGE - Forge Global Holdings, Inc.	——
8	Foghorn Therapeutics Inc.FHTX	0%new
9	VACC - Vaccitech plc	——
10	Bicycle Therapeutics plc - ADRBCYC	0%0

Nkarta, Inc.

Healthcare
Biotechnology

Nkarta, Inc. is a clinical-stage biopharmaceutical company focused on developing allogeneic, off-the-shelf natural killer (NK) cell therapies. The company’s work centers on engineered cell therapies designed to target autoimmune diseases and, in some programs, hematologic cancers. Nkarta’s pipeline includes product candidates built to improve NK-cell recognition, persistence, and activity through proprietary cell engineering and expansion technologies. Its lead programs are being developed for autoimmune conditions such as lupus nephritis, systemic sclerosis, myasthenia gravis, and ANCA-associated vasculitis, reflecting a broader effort to address diseases driven by abnormal immune activity. Based in South San Francisco, California, Nkarta operates as a biotechnology company within the healthcare sector and is dedicated to advancing scalable, ready-to-use cell therapy platforms for clinical use.

Website

Location

1150 Veterans Boulevard

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about NKTX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Apr 17

$NKTX is moving up approximately 30% in 3 weeks, potentially offering a 30% return on investment.
The company's engineered NK approach may show even stronger efficacy in treating RA, allowing it to capture some of the excitement around $ARTV.
The CEO's hint that the company is moving into RA with their engineered NK approach has been well-received, with some analysts expecting the stock to break over $4.

Generated by AI

Sentiment

Of the messages about NKTX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	93.42% +9.21	96.08% +65.04	86.01% +9.87
Bearish	—	6.58% -9.21	3.92% -65.04	13.99% -9.87

Bullish· Mar 27

$NKTX is breaking out over previous intraday highs, and holding above this resistance could lead to further gains.
The company's cost-cutting measures and extended cash runway into 2029 have contributed to its recent 50%+ price increase, with analysts holding $14-$18 targets.
With 4 trials underway for NKX019 in the autoimmune space, momentum is building, and volume remains strong, suggesting the stock could continue to run.

Bearish· Jan 10

$NKTX is likely to decline at the market open after a one-day surge.
The stock is overvalued and may be due for a correction.
$NKTX is heavily shorted and may experience a significant price drop if it fails to reclaim recent gains.

Generated by AI

Topics

Of the messages about NKTX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	60.64%
Technical Analysis	—	0%	0%	35.34%
Analysts	—	0%	0%	4.02%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Announcements· Mar 27

Nkarta, Inc. ($NKTX) laid off 1/3 of its workforce, including senior leadership, resulting in a stock price increase.
The company reported Q4 and full-year 2024 results, highlighting ongoing trials of NKX019 in rheumatic and neurological diseases with initial data expected in H2 2025.
Nkarta implemented a 34% workforce reduction to extend its cash runway by over a year, ensuring ample funds for ongoing trials and research.

Technical Analysis· Mar 27

$NKTX needs to break over downtrend for entries and close over resistance for a bounce.
$NKTX has broken out over previous intraday highs and needs to hold above that resistance for continued momentum.
$NKTX has strong upwards move and is trending upwards, breaking over Volume Weighted Average Price, with a possible run to $5.

Generated by AI

Community

Of the messages about NKTX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	66.92%	69.13%	59.42%
Newcomers	—	33.08%	30.87%	40.58%

Regulars· Mar 25

$NKTX's secondary offering at $10/share, priced at $240M, has raised concerns about the company's financial struggles and potential impact on future growth.
The promising results for five patients with non-Hodgkin lymphoma, which led to a reversal of the company's Friday dive, may not necessarily translate to similar results for lupus treatment.
Nkarta's recent underwritten offering has sparked debate over its future growth potential, with one analyst noting that the company's recent trend of 33 price movements in the past 24 hours may be a cause for concern.

Newcomers· Jan 9

$NKTX is showing signs of consolidation, with price above its 10-day EMA, and a potential inside day forming.
The stock has experienced a significant 77% move, with a 99% Relative Strength (RS) over 1, 3, and 6 months, indicating strong momentum.
The company is pursuing a treatment for lupus, and the stock has seen a nearly 10x increase since its October low, with the next potential target being $CABA.

Generated by AI

Nkarta

Social

Apr 17

Bullish· Mar 27

Bearish· Jan 10

Announcements· Mar 27

Technical Analysis· Mar 27

Regulars· Mar 25

Newcomers· Jan 9

Stifel reiterates Buy rating on Nkarta stock, cites trial progress

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

Nkarta at stifel forum: safer cell therapy push gains traction

Nkarta at H.C. Wainwright conference: autoimmune push gains focus

Nkarta to Participate in September Investor Conferences

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Also Discussed

Nkarta, Inc.

Company Information

Location

Stifel reiterates Buy rating on Nkarta stock, cites trial progress

Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance

Nkarta at stifel forum: safer cell therapy push gains traction

Nkarta at H.C. Wainwright conference: autoimmune push gains focus

Nkarta to Participate in September Investor Conferences

Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026

Also Discussed

Social

Apr 17

Bullish· Mar 27

Bearish· Jan 10

Announcements· Mar 27

Technical Analysis· Mar 27

Regulars· Mar 25

Newcomers· Jan 9